Sunday, May 24, 2026 9:17:16 PM
The article doesn't set a dollar figure for 2030 but clearly states that it should have tremendous growth potential. I'm looking forward to what it will be then, but I also know that it doesn't happen in an instant. Let's say the authors anticipated $30 a share by then, getting there in just 4 years should result in very healthy growth year after year.
On a percentage basis, I believe that this year should be the best. If I'm right about $5 by year's end, that's over 20 times where we began the year. If we went to $10 in 2027, $16 in 2028, $23 in 2029 and met our target of $30 in 2030 it should be considered a great investment, yet each year the percentage of the gain was diminished. These numbers could be higher or lower, it's purely an example, but nonetheless, it would be a great investment.
Historically we'd probably find that by $10 Institutional investment would exceed personnel ownership, so many of us would be out, or substantially diminished our holding. Of course, the company would also accommodate Institutional investors with offering, so the O/S would be substantially greater as well. On a percentage basis individual investor's will have done extremely well, but on a dollar basis it's the Institutions that will make the biggest gains.
Personally, I'm hoping not to sell any stock, but to generate substantial pocket change by writing out of the money covered calls once our share price is much higher, we're on a major exchange, and such options are being offered. I generally don't write such calls until I sense a trading peak and expect retrenchment before moving on to new peaks. If right the call either expires, and I keep all the money, or I repurchase it at much lower prices so I can do it again. If I'm wrong and I wish to keep the stock, I have a big gain in the market, but perhaps a small loss on the call, I buy it back. I'll never sell calls for over about 20% of my shares, and always at prices higher than the trading price at the time I sell them. If I choose to sell it will be at a price higher than the day I sold the call, and in addition to the strike price I get to keep the money paid for the call. If you do want to sell, but aren't rushed, why not sell calls that are slightly above the market and out weeks to a month, if you're called out it's at a higher price and you keep the money paid for the call, if you're not, do it again a month later. Think about it, most of us have hundreds of thousands of shares, for each hundred thousand if you wrote calls on 20%, that's 20,000 shares, if you got $.50 a share that's $10,000. If you buy it back for say $.25 a share you make $5000 and can do it again, if it expires you keep $10000 and can do it again. If it goes $.50 above your strike price you'll have a choice of selling, or buying back the call at more than you paid for it, but your portfolio will be up substantially more than you anticipated as you wouldn't have sold the call if you didn't expect some retrenchment in the stock price.
Gary
On a percentage basis, I believe that this year should be the best. If I'm right about $5 by year's end, that's over 20 times where we began the year. If we went to $10 in 2027, $16 in 2028, $23 in 2029 and met our target of $30 in 2030 it should be considered a great investment, yet each year the percentage of the gain was diminished. These numbers could be higher or lower, it's purely an example, but nonetheless, it would be a great investment.
Historically we'd probably find that by $10 Institutional investment would exceed personnel ownership, so many of us would be out, or substantially diminished our holding. Of course, the company would also accommodate Institutional investors with offering, so the O/S would be substantially greater as well. On a percentage basis individual investor's will have done extremely well, but on a dollar basis it's the Institutions that will make the biggest gains.
Personally, I'm hoping not to sell any stock, but to generate substantial pocket change by writing out of the money covered calls once our share price is much higher, we're on a major exchange, and such options are being offered. I generally don't write such calls until I sense a trading peak and expect retrenchment before moving on to new peaks. If right the call either expires, and I keep all the money, or I repurchase it at much lower prices so I can do it again. If I'm wrong and I wish to keep the stock, I have a big gain in the market, but perhaps a small loss on the call, I buy it back. I'll never sell calls for over about 20% of my shares, and always at prices higher than the trading price at the time I sell them. If I choose to sell it will be at a price higher than the day I sold the call, and in addition to the strike price I get to keep the money paid for the call. If you do want to sell, but aren't rushed, why not sell calls that are slightly above the market and out weeks to a month, if you're called out it's at a higher price and you keep the money paid for the call, if you're not, do it again a month later. Think about it, most of us have hundreds of thousands of shares, for each hundred thousand if you wrote calls on 20%, that's 20,000 shares, if you got $.50 a share that's $10,000. If you buy it back for say $.25 a share you make $5000 and can do it again, if it expires you keep $10000 and can do it again. If it goes $.50 above your strike price you'll have a choice of selling, or buying back the call at more than you paid for it, but your portfolio will be up substantially more than you anticipated as you wouldn't have sold the call if you didn't expect some retrenchment in the stock price.
Gary
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
